Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

Verastem, Inc. (VSTM) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/03/2018 BW Verastem Oncology Reports First Quarter 2018 Financial Results
03/14/2018 BW Verastem to Present at Upcoming Conferences
03/13/2018 BW Verastem Reports Year-End 2017 Financial Results
12/15/2017 BW Verastem Announces Pricing of Public Offering of Common Stock
12/10/2017 BW Verastem Announces Clinical Data from the Pivotal Phase 3 DUO™ Study: Duvelisib Significantly Improves Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/05/2017 BW Verastem to Present Results from Pivotal Phase 3 DUO Study in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at a Research and Development Event at ASH 2017
11/07/2017 BW Verastem Reports Third Quarter 2017 Financial Results
09/22/2017 BW Verastem to Present at the Cantor Fitzgerald Global Healthcare Conference
09/06/2017 BW Verastem Expands Duvelisib Development Program to Include Peripheral T-Cell Lymphoma
09/06/2017 BW Verastem Announces Positive Top-line Data from the Pivotal Phase 3 DUO™ Study in Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
08/08/2017 BW Verastem Reports Second Quarter 2017 Financial Results
05/31/2017 BW Verastem to Present at the Jefferies 2017 Global Healthcare Conference
05/10/2017 BW Verastem Reports First Quarter 2017 Financial Results
04/02/2017 BW Data on Verastem's Focal Adhesion Kinase Inhibitor Defactinib Presented at the 2017 American Association for Cancer Research Annual Meeting
03/23/2017 BW Verastem Reports Year-End 2016 Financial Results
03/16/2017 BW Verastem to Host Conference Call on March 23rd to Discuss Fourth Quarter and Full-Year 2016 Financial Results and Recent Highlights

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy